These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 2611412)
21. Behavior and immune status of MRL mice in the postweaning period. Sakić B; Szechtman H; Talangbayan H; Denburg S; Carbotte R; Denburg JA Brain Behav Immun; 1994 Mar; 8(1):1-13. PubMed ID: 8003767 [TBL] [Abstract][Full Text] [Related]
22. Autoimmune-induced damage of the midbrain dopaminergic system in lupus-prone mice. Ballok DA; Earls AM; Krasnik C; Hoffman SA; Sakic B J Neuroimmunol; 2004 Jul; 152(1-2):83-97. PubMed ID: 15223241 [TBL] [Abstract][Full Text] [Related]
23. FK506: therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. Furukawa F; Imamura S; Takigawa M Arch Dermatol Res; 1995; 287(6):558-63. PubMed ID: 7487142 [TBL] [Abstract][Full Text] [Related]
24. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice. Matsumoto K; Watanabe N; Akikusa B; Kurasawa K; Matsumura R; Saito Y; Iwamoto I; Saito T Arthritis Rheum; 2003 Feb; 48(2):486-94. PubMed ID: 12571859 [TBL] [Abstract][Full Text] [Related]
25. Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis. Shiraki M; Fujiwara M; Tomura S Clin Exp Immunol; 1984 Feb; 55(2):333-9. PubMed ID: 6607792 [TBL] [Abstract][Full Text] [Related]
26. Effect of mizoribine on pulmonary lesions in MRL/lpr/lpr mice. Soga T; Ishigatsubo Y; Kitamura H; Okubo T Autoimmunity; 1996; 25(1):9-18. PubMed ID: 9161696 [TBL] [Abstract][Full Text] [Related]
27. Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice. Woo J; Wright TM; Lemster B; Borochovitz D; Nalesnik MA; Thomson AW Clin Exp Immunol; 1995 Apr; 100(1):118-25. PubMed ID: 7535208 [TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice. Swenson J; Olgun S; Radjavi A; Kaur T; Reilly CM Eur J Pharmacol; 2007 Jul; 567(1-2):67-76. PubMed ID: 17490635 [TBL] [Abstract][Full Text] [Related]
30. Taste responsiveness and diet preference in autoimmune MRL mice. Ballok DA; Szechtman H; Sakic B Behav Brain Res; 2003 Mar; 140(1-2):119-30. PubMed ID: 12644285 [TBL] [Abstract][Full Text] [Related]
31. Interstitial pneumonitis in autoimmune MRL/lpr mice and its treatment with cyclosporin A. Okudaira H; Ogita T; Miyamoto T; Shiga J; Suko M; Okudaira K; Terada E; Ghoda A; Terada K; Saito M Clin Immunol Immunopathol; 1986 Jan; 38(1):47-54. PubMed ID: 3940742 [TBL] [Abstract][Full Text] [Related]
32. Modulation of intra-pulmonary TGF-beta expression by mycophenolate mofetil in lupus prone MRL/lpr mice. Guo H; Leung JC; Chan LY; Lui SL; Tsang AW; Lai KN Lupus; 2005; 14(8):583-92. PubMed ID: 16175929 [TBL] [Abstract][Full Text] [Related]
33. Analysis of central B cell tolerance in autoimmune-prone MRL/lpr mice bearing autoantibody transgenes. Rubio CF; Kench J; Russell DM; Yawger R; Nemazee D J Immunol; 1996 Jul; 157(1):65-71. PubMed ID: 8683157 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic studies of the combination of deoxyspergualin and prednisolone in MRL/lpr mice with advanced lupus-like disease. Mae T; Nemoto K; Sugawara Y; Abe F; Takeuchi T J Antibiot (Tokyo); 1994 Jan; 47(1):90-4. PubMed ID: 8119866 [TBL] [Abstract][Full Text] [Related]
35. The influence of silicone implantation on murine lupus in MRL lpr/lpr mice. Schaefer CJ; Wooley PH J Rheumatol; 1999 Oct; 26(10):2215-21. PubMed ID: 10529143 [TBL] [Abstract][Full Text] [Related]
36. 5-Azacytidine inhibits the lpr gene-induced lymphadenopathy and acceleration of lupus-like syndrome in MRL/MpJ-lpr/lpr mice. Yoshida H; Yoshida M; Merino R; Shibata T; Izui S Eur J Immunol; 1990 Sep; 20(9):1989-93. PubMed ID: 1698637 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of the Japanese-Chinese herbal medicine, kampo, for the treatment of lupus dermatoses in autoimmune prone MRL/Mp-lpr/lpr mice. Kanauchi H; Imamura S; Takigawa M; Furukawa F J Dermatol; 1994 Dec; 21(12):935-9. PubMed ID: 7868765 [TBL] [Abstract][Full Text] [Related]
38. Marked acceleration of the autoimmune disease in MRL-lpr/lpr mice by the influence of the Yaa gene from BXSB mice. Miyawaki S; Nakamura Y; Takeshita T; Yoshida H; Shibata Y; Mitsuoka S Lab Anim Sci; 1988 Jun; 38(3):266-72. PubMed ID: 2970562 [TBL] [Abstract][Full Text] [Related]
39. Early induction of anti-double-stranded DNA antibodies in lupus-prone MRL mice inoculated with Ly-24+ cells cloned from lymph node cells of an MRL/Mp-lpr/lpr mouse: possible effect of putative cytokines produced by cloned Ly-24+ cells. Kanai Y; Isonishi S; Katagiri T; Koizumi T; Miura K; Kurosawa Y Immunol Lett; 1990; 24(1):49-55. PubMed ID: 2197220 [TBL] [Abstract][Full Text] [Related]
40. Inflammatory central nervous system disease in lupus-prone MRL/lpr mice: comparative histologic and immunohistochemical findings. Vogelweid CM; Johnson GC; Besch-Williford CL; Basler J; Walker SE J Neuroimmunol; 1991 Dec; 35(1-3):89-99. PubMed ID: 1955574 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]